Save18%
Original price$ 94.95
Current price$ 77.95
SKU00002-7597-01
Medical Professional License Required to Unlock Account(Note: We don’t Fill Personal Prescriptions)How to Order:
✔Send an email request to: [email protected]
You will receive instructions on how to create an account along with Rx Ordering Details.
Zyprexa Olanzapine for Injection 10 mg is a prescription medication used to treat acute agitation in patients with schizophrenia and bipolar disorder. It contains the active ingredient olanzapine, which belongs to a class of medications called atypical antipsychotics. This medication works by blocking certain receptors in the brain to regulate the levels of chemicals involved in mood and behavior. It is administered as an injection into a muscle by a healthcare professional and may be used for short-term treatment in a hospital setting. It is not a cure for schizophrenia or bipolar disorder but can help manage symptoms.
Mechanism of Action
Zyprexa Olanzapine is an antipsychotic medication that works by blocking the activity of dopamine and serotonin receptors in the brain. Dopamine and serotonin are neurotransmitters that regulate mood, behavior, and cognition.
By blocking these receptors, Zyprexa Olanzapine helps to balance the levels of these neurotransmitters in the brain, which can improve symptoms of psychosis, such as delusions, hallucinations, and disorganized thinking.
Additionally, Zyprexa Olanzapine also blocks the activity of other neurotransmitters, such as histamine and norepinephrine, which can contribute to the sedative and anti-anxiety effects of the medication.
Overall, the mechanism of action for Zyprexa Olanzapine is to modulate the activity of various neurotransmitters in the brain, leading to a reduction in psychotic symptoms and improvements in behavior and mood.
Zyprexa Olanzapine for Injection 10mg Vial is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It may also be used in combination with other medication to treat depression.
Olanzapine is an antipsychotic medication that affects chemicals in the brain. Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old.
Brand: LillySize: 10mgNDC: 00002-7597-01UPC: 00002-7597-01
Buy Zyprexa Olanzapine for Injection 10mg Vial online at Mountainside Medical Equipment.
Easy ordering, DAQ| Quantity | Price | Per unit | Order |
|---|---|---|---|
| Treatment | 10mg Vial | N/A | $14.60 |
| Cognitive behavioral therapy | $2.40 | ||
| Pharmacotherapy | $1.25 |
| $15.50 |
| $6. |
Zyprexa is a widely used antipsychotic medication for the treatment of schizophrenia. It falls under the category of a class of drugs called atypical antipsychotics. This article explains the uses and benefits of Zyprexa and the risks and benefits of using it.
The main risks of Zyprexa are the following:
This is not an exhaustive list of risks and benefits of Zyprexa, including the following:
The following are the main risks of Zyprexa:
These risks are also based on several factors such as the following:
Zyprexa is not only effective for the treatment of schizophrenia but also for treating symptoms of the condition. These symptoms include:
The risks and benefits of Zyprexa are based on its active ingredient,olanzapine.
This is based on the following:
Zyprexa is not only effective for the treatment of schizophrenia but also for the treatment of bipolar disorder., also called olanzapine, which is aripiprazole.
Pfizer Inc.'s schizophrenia drug Zyprexa is one of the most common and widely prescribed medications in the U. S. today. Despite the FDA's approval for the drug last week, the company has been accused of approving and marketing unapproved unapproved uses of the drug.
Pfizer said Friday that it is warning patients and doctors not to use Zyprexa, its first-half antipsychotic drug, for schizophrenia.
According to the FDA, Zyprexa is not approved for use in patients with a confirmed diagnosis of schizophrenia, and patients with a known history of severe manic, depressive or mixed episodes of schizophrenia or bipolar I.
However, a company spokeswoman said the FDA has not approved the use of Zyprexa for the treatment of schizophrenia. She said the FDA is reviewing the safety and efficacy of the drug.
"This is a serious and continuing violation of our pharmacy laws," said Mary Jane Jones, spokeswoman. "The FDA has no jurisdiction over this matter."
The FDA's approval of the drug for treating schizophrenia also was made in a letter to pharmacists and health care professionals who spoke on condition of posting the letter to their websites.
The company told the FDA it will review the application of the drug and determine whether it meets the requirements for approval by the agency.
The drug has been approved for use in patients with a confirmed diagnosis of schizophrenia, said Michael S. Wolfe of the Health Research Authority, an advocacy group that represents state and federal governments. The drug is being used to treat people with schizophrenia who are in the early stages of the disease.
"In the early stages, the medication may help patients with serious psychotic disorders," Wolfe said. "A drug that is approved for use in schizophrenia is approved for treating these disorders."
The company said it would not be marketing the drug for any purpose. It said that the drug is not approved for use in patients with a known history of severe manic, depressive or mixed episodes of schizophrenia. Instead, it is being used to treat people with a known history of severe manic, depressive or mixed episodes of schizophrenia or bipolar I.
Schizophrenia is a mental disorder that affects about 1 percent of the U. population. It is characterized by a severe and long-lasting clinical depression, delusions and hallucinations. About 30 million people in the U. are estimated to suffer from this condition.
In April, Pfizer, the maker of Zyprexa, voluntarily recalled its drug after reports of serious adverse events. The company said the recall was due to concerns about the risk of serious side effects from the drug.
The company said it will review the safety and efficacy of Zyprexa and other drugs that are marketed as unapproved for the treatment of schizophrenia. The drug is being used to treat people with schizophrenia and other serious mental disorders.
Pfizer said the company will be reviewing the drug's label and the safety and efficacy data for all new drugs approved for schizophrenia.
"It is important that these products are approved for use in people with a known history of severe manic, depressive or mixed episodes of schizophrenia," said Lisa L. Fink of the University of Chicago School of Medicine. The drug is being approved for the treatment of people with a known history of severe manic, depressive or mixed episodes of schizophrenia and bipolar I.
The drug, which is marketed as a non-stimulant, was approved in the U. in 1996 for the treatment of schizophrenia and bipolar I. The company said that the drug is being used to treat people with a known history of severe manic, depressive or mixed episodes of schizophrenia and bipolar I.The company said the company is reviewing all marketing materials and has determined the benefits and risks of the product.
Pfizer has said it will have no comment on the FDA's decision to approve the drug.
Originally Published: February 18, 2023 at 12:00 AM EDT
"In general, doctors should be aware that the antipsychotic drugs that are available for the treatment of schizophrenia are not approved for use in schizophrenia and should be avoided," the company said.The drug is being used to treat people with a confirmed diagnosis of schizophrenia. The company said that the FDA has not approved the use of the drug for the treatment of people with a known history of severe manic, depressive or mixed episodes of schizophrenia and bipolar I.Pfizer's statement follows an FDA advisory committee that recommended that the drug be marketed for uses other than its approved purpose.WASHINGTON — The Food and Drug Administration on Wednesday approved the first generic version of olanzapine in the United States, a drug used to treat schizophrenia. The first generic version of olanzapine is the same product as Zyprexa, a second-generation antipsychotic approved by the FDA last year. In the first year of the FDA approval of Zyprexa, the company announced that it was reviewing its second-quarter financial guidance.
The FDA approved the second-quarter financial guidance for Zyprexa as part of a new drug review that the company is reviewing.
The company said the review was done to determine the overall financial impact of Zyprexa, which has been on the market for more than 20 years.
The company said the review was to determine whether Zyprexa had a substantial potential impact on the company's overall financial position, which includes earnings and cash flows.
Zyprexa is a newer version of Eli Lilly and Company, which was approved in 1997 by the FDA. It has been on the market since 2005 and has been available on the New Drug Application for many years.
In the first quarter, Zyprexa lost $1.7 billion, or 27 percent, to $12.1 billion in sales, and $1.5 billion to $2.3 billion in revenue. The company said its results for the first quarter of 2010 and the first quarter of 2011 will be compared to results for the full year of 2005.
The company said it is evaluating the results of Zyprexa's results in the fourth quarter of 2010, the first quarter of 2011 and the first quarter of 2012. The company also said the results for the fourth quarter of 2010 and the first quarter of 2011 will be compared to results for the full year of 2005.
Zyprexa's fourth quarter financial results were as follows:
In the first-quarter financial guidance, Zyprexa said it had lost $4.6 billion of revenue and has a net loss of $1.8 billion for the full year. In the first-quarter financial guidance, Zyprexa said it had lost $1.5 billion of revenue and has a net loss of $1.6 billion of revenues. In the first-quarter financial guidance, Zyprexa said it has lost $1.2 billion of revenue and has a net loss of $2.1 billion of revenues. Zyprexa also said the company's full-year results for 2010 and 2011 will be compared to results for the full year of 2005.
Zyprexa is a newer version of Eli Lilly and Company, which was approved in 1997 and has been available on the New Drug Application for several years.
In the first-quarter financial guidance, Zyprexa said it had lost $3.9 billion of revenue and has a net loss of $1.3 billion of revenues. Zyprexa also said it had lost $1.1 billion of revenue and had a net loss of $1.1 billion of revenues in the first-quarter financial guidance. The company said it will report its results in the fourth quarter of 2010 and the first quarter of 2011. Zyprexa's results will be compared to results for the full year of 2005.
In the first-quarter financial guidance, Zyprexa said it had lost $4.3 billion of revenue and has a net loss of $1.5 billion of revenues. Zyprexa also said it had lost $1.1 billion of revenue and had a net loss of $2.3 billion of revenues.
In the first-quarter financial guidance, Zyprexa said it had lost $1.5 billion of revenue and had a net loss of $1.5 billion of revenues. Zyprexa also said it had lost $1.2 billion of revenue and had a net loss of $2.
Stade de France Pharmacy